10-Q: Quanterix Reports Q1 2025 Results, Announces Restructuring and Akoya Biosciences Merger Update

Quanterix Corporation announces its Q1 2025 financial results, a restructuring plan to reduce operating costs, and an update on its agreement to acquire Akoya Biosciences.

Summary

• Quanterix Corporation reported a net loss of $20.5 million for the three months ended March 31, 2025, compared to a net loss of $11.2 million for the same period in 2024.
• Total revenue decreased by 5% to $30.3 million, driven by a decline in service revenue.
• The company is implementing a restructuring plan expected to reduce operating costs by approximately $15 million in 2025 and $30 million annually.
• Quanterix acquired Emission, Inc. on January 8, 2025, for an upfront payment of $9.0 million, with potential future payments based on milestones.
• The company amended its merger agreement with Akoya Biosciences, with revised terms including a new exchange ratio and cash consideration.
• Akoya may draw on convertible notes up to $30.0 million from Quanterix between June 15, 2025, and August 31, 2025, under certain conditions.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the acquisition of Emission and the potential of the Akoya merger, the increased net loss and revenue decline raise concerns. The restructuring plan and cost-saving measures are viewed as necessary but also reflect underlying challenges.

Positives

• Product revenue increased by 5% due to higher selling prices of consumables.
• The restructuring plan is expected to reduce operating costs significantly.
• The acquisition of Emission, Inc. secures the use of highly controlled beads for next-generation platforms.
• The amended merger agreement with Akoya Biosciences is expected to establish a fully integrated technology ecosystem.

Negatives

• Net loss increased to $20.5 million from $11.2 million year-over-year.
• Total revenue decreased by 5%, driven by a decline in service revenue.
• The company acknowledges softness in instrument sales due to a constrained capital funding environment.
• The company's internal control over financial reporting was not effective at the reasonable assurance level as of March 31, 2025.

Risks

• The company may fail to achieve the expected cost savings from the restructuring plan.
• Changes in U.S. government policies, including reductions in federal research funding, could adversely affect the business.
• Defects or quality issues in products could lead to unforeseen costs and product recalls.
• The merger with Akoya may not be completed, and the company may not realize the anticipated benefits.
• Actions of activist or dissident stockholders could negatively affect the business and operations.

Future Outlook

The company expects to incur operating losses at least through the next 24 months and expects expenses to increase as it expands research and development efforts, invests in Lucent Diagnostics, seeks regulatory approvals, and strategically acquires companies.

Management Comments

• The company believes instrument sales will recover with an improvement in the capital funding environment.
• The company further believes the introduction of our Simoa ONE instrument, which is expected to launch by the end of 2025, will help grow instrument sales in future years.
• While we continue to see strong opportunities with customers, the uncertain macroeconomic environment is expected to drive fluctuations in Accelerator Laboratory revenue in 2025.

Industry Context

The life sciences industry is facing a constrained capital funding environment, which is impacting instrument sales for Quanterix. The company is focusing on strategic acquisitions and new product launches to expand its market presence and technology offerings.

Comparison to Industry Standards

• It is difficult to compare Quanterix's results directly to industry standards without specific competitor data.
• However, the company's focus on ultra-sensitive biomarker detection aligns with the broader trend in the diagnostics industry towards earlier disease detection and personalized medicine.
• The acquisition of Akoya Biosciences is a strategic move to expand into spatial biology, a rapidly growing field in oncology and immunology.
• Companies like NanoString Technologies and 10x Genomics are also key players in the spatial biology market.

Related Party Transactions

• In January 2025, prior to the acquisition of Emission, the Company entered into agreements with two entities to continue development work on certain future products for Quanterix.
• A member of the Company's Board of Directors was previously affiliated with Tufts and continues to receive compensation from Tufts on a formulaic basis based on royalties and license payments the Company makes to Tufts.
• Harvard is required to pay a portion of the payments received from the Company under the Harvard License Agreement to a member of the Company's Board of Directors.

Stakeholder Impact

• Shareholders will experience dilution upon completion of the Akoya merger.
• Employees are affected by the restructuring plan and reduction in force.
• Customers may experience disruptions due to the merger and integration activities.
• Suppliers and partners may be impacted by changes in the company's strategy and operations.

Next Steps

• Complete the merger with Akoya Biosciences.
• Implement the restructuring plan to reduce operating costs.
• Launch the Simoa ONE instrument by the end of 2025.
• Continue efforts to remediate material weaknesses in internal control over financial reporting.

Key Dates

Keywords

Quanterix, Akoya Biosciences, Emission Inc., Financial Results, Merger, Restructuring, Revenue, Net Loss, Acquisition, Simoa, Biomarkers, Diagnostics